[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St. George's Hospital, London\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":101},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100382312","distribution-of-cell-cell-junction-proteins-in-arrhythmic-disorders-100382312",true,"NCT04257994","Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders","Analysis of Distribution of Cell-cell Junction Proteins in Buccal Smear Samples From Patients With Arrhythmic Disorders and Family Members at Risk as a Means for Diagnosis","Inclusion Criteria:• Participants will include patients diagnosed with a heritable arrhythmic disorder (including arrhythmogenic, hypertrophic and dilated cardiomyopathy, cardiac sarcoidosis as well as cardiac channelopathies; Long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia) followed at the Inherited Cardiac Conditions (ICC) service of St. George's University Hospitals NHS Foundation Trust.\n\n* Family members of victims of SCD evaluated at the same clinic for risk assessment and diagnosis. These groups include both individuals with clear disease manifestation (termed \"affected\") as shown by conventional diagnostic approaches (electrocardiography, echocardiography, cardiac MRI, Holter monitoring) as well as potential carriers of disease-causing mutations who, however, may not\u002Fnot yet manifest any overt sign of cardiovascular abnormalities (termed \"carriers\"). These are typically family members of probands diagnosed with a heritable arrhythmic disorder or family members of a sudden cardiac death victim.\n* All individuals that fall in the above categories will be included regardless of their management (medication, devices, and surgical procedures).\n* Individuals with co-existing conditions will also be included and their medical history will be taken into account when interpreting the results of the immunohistochemical analysis.\n* Adult individuals (\\>18 years of age).\n* Pregnant women will be included as the approach used is not in any way harmful or uncomfortable.\n* All individuals must have provided the study team with a signed informed consent in order to participate in the study.\n\nExclusion Criteria:• Children under 18 years of age\n\n* Individuals lacking decisional capacity.\n* Individuals with non-heritable, non-arrhythmic cardiac disorders (such as ischemic heart disease or inflammatory disorders) followed at St. George's University Hospitals NHS Foundation Trust.\n* Non-English speakers will be excluded from the study unless a translator is present who can thoroughly explain to them the research question\u002Fplan in order for them to provide an informed consent.",false,"ALL","18 Years",{"count":20,"type":21},26,"ESTIMATED","OBSERVATIONAL","Every week in the UK, 12 apparently healthy and fit individuals under the age of 35 die suddenly, a tragic event known as sudden cardiac death (SCD). The investigators have shown that heritable cardiac disorders affect the distribution of proteins at the cardiac cell-cell junctions, the areas where cardiac cells are mechanically and electrically coupled. This knowledge has helped the investigators diagnose specific heart disorders in individuals thus reducing the risk and incidence of SCD. Yet, the primary material required is a heart sample. A heart biopsy is an invasive process that comes with risks and is not performed unless absolutely necessary. And it is impossible to obtain a heart sample from an individual that may be carrying a disease-causing mutation (and hence be at risk of SCD) but does not yet show evidence of disease manifestation. The investigators recently showed that buccal cells show changes in protein distribution equivalent to those exhibited by the heart,hence providing them with a surrogate tissue for the myocardium. The investigators aim to use buccal smears as a means to identify those at risk of SCD. Patients regularly seen at the cardiology clinics at St. George's Hospital can participate in the study. The investigators shall take a buccal smear simply by rubbing a soft brush at the inside of their cheek and smearing it on a slide. Most individuals willing to participate in the study will only have to provide the investigators with a sample once. However, in selected cases (for instance, if the patients show disease progression or have a change in medication) they may be asked to provide the investigators with a subsequent sample during one of their scheduled follow-up visits. The process takes only a few seconds, is totally risk- and pain-free and it is anticipated to have great implications in diagnosis and patient management.",[25,26,27],"Arrhythmogenic Right Ventricular Dysplasia","Brugada Syndrome","Cardiac Channelopathy",[29],"cardiac arrhythmias","RECRUITING","2026-05-07",{"date":33,"type":34},"2026-05-08","ACTUAL",{"date":36,"type":34},"2017-10-15",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"St. George's Hospital, London","OTHER",1,{"id":44,"slug":45,"hasResults":16,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100470880","hybrid-ablation-of-atrial-fibrillation-in-heart-failure-100470880","NCT05411614","Hybrid Ablation of Atrial Fibrillation in Heart Failure","A Randomised Controlled Trial Comparing Convergent Hybrid Ablation to Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure","HALT AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Persistent or Long-standing Persistent AF\n* Dilated left atrium (at least moderately dilated)\n* Suitable for either procedure\n* LVEF \\\u003C 50%\n\nExclusion Criteria:\n\n* Not yet optimised from a medical or lifestyle perspective for AF or heart failure\n* Unable to provide written consent\n* Previous open-heart surgery\n* Active infection, oesophageal ulcer stricture or oesophageal varices\n* Prior catheter ablation of atrial fibrillation (prior ablation for atrial flutter \u002F supraventricular tachycardia or ventricular arrhythmia acceptable)\n* Contraindication to anticoagulation, or active thrombus in the left atrium despite therapeutic anticoagulation\n* Severe valvular heart disease\n* Unstable coronary artery disease\n* Uncontrolled ventricular arrhythmia\n* Heart attack or stroke within the last 90 days\n* Pregnant, breastfeeding, or women of childbearing age who plan to get pregnant within six months\n* Severe concomitant condition or presence of an implanted device that would preclude the patient from undergoing trial procedures",{"count":52,"type":21},120,"INTERVENTIONAL",[55],"NA","A randomised controlled trial to assess the efficacy of staged hybrid ablation when compared with standard catheter ablation in patients with non-paroxysmal atrial fibrillation (AF) and Heart Failure",[58,59,60,61,62,63],"Persistent Atrial Fibrillation","Atrial Fibrillation, Persistent","Atrial Arrhythmia","Atrial Fibrillation","Heart Failure","Left Ventricular (LV) Systolic Dysfunction","2025-11-23",{"date":66,"type":34},"2025-11-28",{"date":68,"type":34},"2022-06-25",{"date":70,"type":21},"2027-10",{"name":40,"class":41},7,{"id":74,"slug":75,"hasResults":16,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":53,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":42},"100586817","phase-4-digital-diet-and-exercise-intervention-to-reduce-liver-fibrosis-in-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100586817","NCT06920316","Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Pilot Randomised Controlled Trial","DEFIB-MASLD","Inclusion Criteria:\n\n* Adults 18 years and over\n* Diagnosis of MASLD made by a hepatologist\n* Vibration-Controlled Transient Elastography (VCTE) (FibroScan) liver stiffness measurement (LSM) 8 kPa and above\n* Able to provide written consent\n* Own a smartphone with data plan\n\nExclusion Criteria:\n\n* Alcohol consumption \\>14 units\u002Fweek\n* BMI \\>40\n* Liver disease due to: Alcohol including MASLD with increased alcohol intake (MetALD), Any viral hepatitis, Autoimmune and cholestatic aetiologies including, but not limited to, primary biliary cholangitis and primary sclerosing cholangitis, Hereditary aetiologies including, but not limited to, haemachromatosis, Wilson's disease, alpha-1-antitrypsin deficiency\n* Currently under investigation for cancer or receiving treatment for active cancer\n* Myocardial infarction within last 6 months or uncontrolled cardiovascular disease\n* Pregnant or planning\n* Currently or due to be taking any of the following drugs: GLP-1\u002FGIP agonists, Systemic high dose corticosteroids for \\>6 weeks, Tamoxifen, Amiodarone, Methotrexate, Lomitapide, Valproate, Irinotecan, 5-Fluoruracil\n* Currently using or enrolled in any other lifestyle intervention application or weight loss programme\n* Undergone or due to undergo bariatric surgery including bariatric endoscopic procedures\n* Any other intercurrent illness that is either life-threatening or of clinical significance such that it might limit compliance with study procedures, in the Investigator's opinion",{"count":82,"type":21},100,[84],"PHASE4","Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD)\n\nObjective:\n\nThis study aims to assess whether a digital application called Gro Health can help patients with MASLD and significant liver fibrosis reduce their liver stiffness. Liver stiffness is a measure of liver health and fibrosis. The study will also investigate the impact of this intervention on weight, body measurements, liver health markers, and overall quality of life.\n\nBackground:\n\nMASLD is a liver condition linked to metabolic issues such as obesity and diabetes. It is a common cause of liver-related complications and can lead to severe liver damage. Lifestyle changes, like improved diet and exercise, are key to managing MASLD, but achieving these changes can be challenging for many patients. Digital tools like the Gro Health app may provide personalized and accessible support to improve outcomes.\n\nStudy Design:\n\nThis is a randomized controlled trial involving 100 participants with MASLD and significant fibrosis. Participants will be assigned to either the intervention group (using the Gro Health app) or a control group (receiving standard care). The study will take place at a single site over 12 months.\n\nIntervention:\n\nParticipants in the intervention group will use the Gro Health app, which offers personalized calorie and activity goals, a food diary, over 1,000 Mediterranean diet recipes, and educational resources. They will also receive a smartwatch to track steps and physical activity. The app includes a feature allowing researchers to monitor participants' engagement and provide encouragement.\n\nEligibility:\n\nAdults aged 18 or older with a diagnosis of MASLD and a liver stiffness measurement of 8 kPa or higher are eligible. Key exclusions include alcohol consumption over 14 units\u002Fweek, a BMI over 40, or certain other liver diseases or medications.\n\nOutcomes:\n\nThe primary outcome is a reduction in liver stiffness after six months. Secondary outcomes include changes in weight, BMI, body fat percentage, liver enzymes, cholesterol, and quality of life. Additional data on app usage, physical activity, and dietary habits will also be collected for the intervention group.\n\nPotential Impact:\n\nIf successful, this study will provide evidence that digital tools can help improve liver health and overall well-being in patients with MASLD, offering a scalable solution for healthcare systems.",[87],"Metabolic Dysfunction-Associated Steatotic Liver Disease",[89,90,91],"Non-alcoholic Fatty Liver Disease","Fatty liver","Digital health","NOT_YET_RECRUITING","2025-04-02",{"date":95,"type":34},"2025-04-09",{"date":97,"type":21},"2025-05",{"date":99,"type":21},"2027-09",{"name":40,"class":41},""]